Tel Aviv-based Corephotonics filed its patent infringement case against Apple in federal court in San Jose, California, on Monday.
Corephotonics, which has raised $50 million from several high-profile venture capital firms and other investors, said its patented dual camera technology for mobile devices was incorporated by Apple in the iPhone 7 Plus and iPhone 8 Plus without its authorization.
Apple rejects allegations made by Paradise Papers
According to the lawsuit, Corephotonics Chief Executive David Mendlovic approached Apple about a partnership. Apple praised the start-up’s technology but refused to license it, Corephotonics said, even suggesting it could infringe the latter’s patents with little consequence.
According to the complaint, “Apple’s lead negotiator expressed contempt for Corephotonics’ patents, telling Dr. Mendlovic and others that even if Apple infringed, it would take years and millions of dollars in litigation before Apple might have to pay something.”
An Apple spokesman did not immediately return a request for comment.
Many high-end smartphones include dual camera systems that can zoom in without losing image quality. Apple has its own patents on dual camera technology.
Through its latest funding round in January, Corephotonics raised $15 million from investors that included Samsung, electronics manufacturer Foxconn and chipmaker MediaTek.
Samsung mocks Apple amid iPhone X release
Foxconn is one of Apple’s contract manufacturers. Apple is considering MediaTek as a chip supplier, according to the Wall Street Journal.
Corephotonics’ other investors include Magma VC, Amiti, Hong Kong billionaire Li Ka-shing and Solina Chau’s Horizon, as well as flash storage maker SanDisk and Chinese telephone services provider CK Telecom.
Corephotonics is represented by Quinn Emanuel Urquhart & Sullivan, the law firm that advised Samsung on its patent litigation with Apple.
COMMENTS
Comments are moderated and generally will be posted if they are on-topic and not abusive.
For more information, please see our Comments FAQ